Halozyme Therapeutics, Inc. (NASDAQ:HALO)
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
There are currently 1300 HALO shares in my "fund" with break-even of around 7.15 USD. http://caps.fool.com/Blogs/fund-trades/678775.
Recs
QVT Financial
Recs
Breast cancer drug will pass all clinical trials and send this stock through the roof...
Recs
I cannot resist the potential, so I am parking my money in a good basket of small cap biotech picks. This is the sector to be in for the next 5 years in a big, big way. Only picking the stocks in this sector with the brightest potential.
Recs
The Stock is showing his potential. 1. with good numbers and products that will use the technology from Halozyme Therapeutics
Recs
Myst 3Cmb1 A xxx
Recs
Recs
Recs
New licensing partnerships and increasing sales of approved products will make this stock a good value in the medium term during uncertain markets.
Recs
This stock seems to truly have a halo around it and should perform nicely as a mover and a shaker. Jump on now to cash in.
Recs
Explosive drug collaboration, $100 million cash, no debt, director just bought 20% of stock, incredible market opportunity, my largest position
Recs
HALO is one of the few stocks I own that I believe will tripple in less than 2 years. Lots of brain power behind this one. Great management, great tech and new relationships with big players will get them there... a lot faster than most would think.
Recs
Stock has taken some hits lately, but poised for growth.
Recs
Many new deals in play, watch this stock, it could double in a few years.
Recs
great technology
Recs
This is an Awesome stock that just keeps increasing! What else can I say?!
Recs
The potential from a $600 Million deal with Roche sounds good to me.
Recs
Just signed a $600 million deal with Roche, a $100+ million deal with Baxter, and has a drug comimg to market in 6 months, there are only 35 employees, production is jobbed out saving capital exp and mfg problems. The only stock I have that could be 20x in 3 years.
Recs
Tons of potential and partnerships already with roche and baxter. Look for more partnerships and revenue to start flowing in...now alot of downside on this stock for the new future.
Recs
Will rule the medical world
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 41 : 1 2 3 Next »